8-K - Nuvation Bio Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193

Regulation Fd

8.01

Other Events. On November 26, 2025, the Company announced its decision to discontinue development of NUV-1511, the first compound in its first-of-its-kind drug

Other Event

$100.00

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation of Nuvation Bio Inc. (November 26, 2025) 104 Cover Page I

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1